By combining two tumor-specific markers of the B-cell lineage, CD160 and ROR-1 (18, 19, 30, 32, 45), CD160-ROR1FCA targets fewer CLL surface antigens than the originally published ERIC methodology, thereby reducing the number of monoclonal antibodies used, and allowed a simpler gating strategy and remains highly sensitive. Here, CD160 is linked to neoplasm.